Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Sleep apnea could be costing you brain power and increasing your risk of dementia and Alzheimer's disease, a new study says.

A previous version of this report failed to reflect that the scientific name tirzepatide refers to Zepbound. It has been corrected. A study of two blockbuster weight-loss drugs showed that users ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants who took Zepbound lost more weight than those who took Wegovy.